MX2023005696A - Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. - Google Patents
Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.Info
- Publication number
- MX2023005696A MX2023005696A MX2023005696A MX2023005696A MX2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- preparing
- storing
- methods
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114478P | 2020-11-16 | 2020-11-16 | |
| US202063115588P | 2020-11-18 | 2020-11-18 | |
| US202063115128P | 2020-11-18 | 2020-11-18 | |
| EP2020082602 | 2020-11-18 | ||
| US202163135723P | 2021-01-10 | 2021-01-10 | |
| US202163149372P | 2021-02-15 | 2021-02-15 | |
| PCT/EP2021/059460 WO2022218503A1 (en) | 2021-04-12 | 2021-04-12 | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| PCT/EP2021/081675 WO2022101470A1 (en) | 2020-11-16 | 2021-11-15 | Lnp compositions comprising rna and methods for preparing, storing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005696A true MX2023005696A (es) | 2023-05-29 |
Family
ID=78621901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005696A MX2023005696A (es) | 2020-11-16 | 2021-11-15 | Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230414747A1 (https=) |
| EP (1) | EP4243788A1 (https=) |
| JP (1) | JP2023549266A (https=) |
| KR (1) | KR20230121752A (https=) |
| AU (1) | AU2021379090A1 (https=) |
| CA (1) | CA3198742A1 (https=) |
| IL (1) | IL302771A (https=) |
| MX (1) | MX2023005696A (https=) |
| TW (1) | TW202237148A (https=) |
| WO (1) | WO2022101470A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| US12449081B2 (en) | 2021-09-24 | 2025-10-21 | Cosmo Koki Co., Ltd. | Boring machine |
| CN118488834A (zh) * | 2021-11-23 | 2024-08-13 | 赛欧生物医药股份有限公司 | 细菌源性脂质组合物和其用途 |
| US20250302747A1 (en) * | 2022-06-08 | 2025-10-02 | Academia Sinica | Lipids, nanoparticles comprising the same and uses thereof |
| CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
| EP4604927A1 (en) * | 2022-10-17 | 2025-08-27 | Agilent Technologies, Inc. | Methods of analyzing lipid nanoparticles in physiological fluids |
| EP4637787A2 (en) * | 2022-12-20 | 2025-10-29 | Seqirus Inc. | Lipid nanoparticle composition |
| WO2024131874A1 (en) * | 2022-12-21 | 2024-06-27 | Abogen Biosciences (Shanghai) Co., Ltd. | Polynucleotides encoding cd19/cd3 bispecific antibodies |
| WO2024193827A1 (en) * | 2023-03-23 | 2024-09-26 | BioNTech SE | Stabilized nucleic acid compositions and methods for preparing, storing and using the same |
| WO2024203660A1 (ja) * | 2023-03-29 | 2024-10-03 | 国立大学法人東北大学 | 核酸内封脂質ナノ粒子の製造方法 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025068553A1 (en) | 2023-09-28 | 2025-04-03 | Universität Basel | Catalytic moieties for treating cancer |
| WO2025080672A1 (en) * | 2023-10-09 | 2025-04-17 | The Trustees Of The University Of Pennsylvania | Immune cell targeted delivery vehicles and methods of use thereof |
| GB202404607D0 (en) * | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| IL307179A (en) * | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| BR112018069417A2 (pt) | 2016-04-22 | 2019-01-22 | Biontech Rna Pharmaceuticals Gmbh | método para fornecer rna fita simples e ssrna |
| WO2017218704A1 (en) * | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| WO2020072605A1 (en) * | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| US20240033344A1 (en) * | 2020-11-16 | 2024-02-01 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
| AU2021376893A1 (en) * | 2020-11-16 | 2023-06-15 | BioNTech SE | Enhanced formulation stabilization and improved lyophilization processes |
-
2021
- 2021-11-15 AU AU2021379090A patent/AU2021379090A1/en active Pending
- 2021-11-15 EP EP21807117.3A patent/EP4243788A1/en active Pending
- 2021-11-15 KR KR1020237020261A patent/KR20230121752A/ko active Pending
- 2021-11-15 MX MX2023005696A patent/MX2023005696A/es unknown
- 2021-11-15 WO PCT/EP2021/081675 patent/WO2022101470A1/en not_active Ceased
- 2021-11-15 JP JP2023528666A patent/JP2023549266A/ja active Pending
- 2021-11-15 IL IL302771A patent/IL302771A/en unknown
- 2021-11-15 US US18/036,677 patent/US20230414747A1/en active Pending
- 2021-11-15 TW TW110142348A patent/TW202237148A/zh unknown
- 2021-11-15 CA CA3198742A patent/CA3198742A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230121752A (ko) | 2023-08-21 |
| AU2021379090A9 (en) | 2025-01-09 |
| EP4243788A1 (en) | 2023-09-20 |
| US20230414747A1 (en) | 2023-12-28 |
| TW202237148A (zh) | 2022-10-01 |
| IL302771A (en) | 2023-07-01 |
| WO2022101470A1 (en) | 2022-05-19 |
| AU2021379090A1 (en) | 2023-06-15 |
| CA3198742A1 (en) | 2022-05-19 |
| JP2023549266A (ja) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005696A (es) | Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. | |
| MX2022000934A (es) | Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion. | |
| MX2022013606A (es) | Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas. | |
| CO2021005774A2 (es) | Lípidos con amina ionizables | |
| CL2022000603A1 (es) | Inhibidores prmt5 cooperativos de mta | |
| IL320823A (en) | Formulations | |
| CO2020014262A2 (es) | Molécula que tiene utilidad pesticida, y composiciones y procedimientos relacionados con la misma | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| CL2024000120A1 (es) | Arn adorbido sobre partículas de nanoemulsión lipídica y sus formulaciones. | |
| EP4036079A3 (en) | Compounds and compositions for intracellular delivery of agents | |
| CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
| BR112018067927A2 (pt) | formulação, método de tratamento de plantas, método agrícola e kit | |
| AR083268A1 (es) | Conjugado de naloxol-peg cristalino | |
| MX2021012032A (es) | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. | |
| CL2025000194A1 (es) | Construcciones de arni para inhibir expresión de scap y sus usos | |
| UY40418A (es) | Métodos y composiciones para mejorar características de rendimiento en plantas | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| CO2023000239A2 (es) | Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas | |
| CO2022000575A2 (es) | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico |